1-10 of 10
Danelle James
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Jacob D. Soumerai, MD, Ai Ni, PhD, Mohamed Darif, PhD, Anil Londhe, PhD, Guan Xing, PhD, Yong Mun, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD, Kari G. Chaffee, MS, Richard R. Furman, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Jeff Sharman, MD, John F. Seymour, MBBS, PhD, Asher A. Chanan-Khan, MD, John C. Byrd, MD, Jeffrey A. Jones, MD MPH, Lucille A. Ferrante, MD, Lyndah K. Dreiling, MD, Mehrdad Mobasher, MD MPH, Thomas Stark, MD PhD, Vijay Reddy, MD PhD, Angela J. Howes, BSc, PhD, Danelle James, MD MAS, Pankaj Bhargava, MD, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4394.
https://doi.org/10.1182/blood-2018-99-112989
Published: 2018
Journal Articles

Analysis of Prognostic Factors Predictive of Complete Response (CR) to Ibrutinib in Patients with CLL/SLL

Susan O'Brien, MD, Samantha Jaglowski, MD MPH, John C. Byrd, MD, Rajat Bannerji, MD PhD, Kristie Blum, MD, Christopher P. Fox, MBChB, PhD, Richard R. Furman, MD, Peter Hillmen, Thomas J. Kipps, MD, Marco Montillo, MD, Jeff Sharman, MD, Sam Suzuki, MS, MBA, Danelle James, MD MAS, Alvina D. Chu, MD, Steven Coutre, MD
Journal: Blood
Blood (2015) 126 (23): 4153.
https://doi.org/10.1182/blood.V126.23.4153.4153
Published: 2015
Journal Articles

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

Clinical Trials & Observations
Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra Ferrajoli, Nitin Jain, Binsah George, Danelle James, Hagop Kantarjian, Jan Burger, Susan O’Brien
Journal: Blood
Blood (2015) 125 (13): 2062–2067.
https://doi.org/10.1182/blood-2014-09-603670
Published: 2015
Journal Articles

Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib

Brief Report
Dominik Wodarz, Naveen Garg, Natalia L. Komarova, Ohad Benjamini, Michael J. Keating, William G. Wierda, Hagop Kantarjian, Danelle James, Susan O’Brien, Jan A. Burger
Journal: Blood
Blood (2014) 123 (26): 4132–4135.
https://doi.org/10.1182/blood-2014-02-554220
Published: 2014
Includes: Supplemental data
Journal Articles

B Cell Activating Factor and c-Myc Regulate the Progression of Chronic Lymphocytic Leukemia.

Weizhou Zhang, PhD, Arnon P. Kater, MD, PhD, Han-Yu Chuang, Thomas Enzler, MD, PhD, George F. Widhopf, II, PhD, Danelle James, MD, Harvey Herschman, Michael Karin, PhD, Thomas J. Kipps, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 359.
https://doi.org/10.1182/blood.V114.22.359.359
Published: 2009
Journal Articles

Lenalidomide Administered for the Initial Treatment of Chronic Lymphocytic Leukemia (CLL) Patients- In Vivo Modulation of the Leukemia Cell Surface Phenotype and Association with Tumor Flare Reaction (TFR).

Danelle James, MD, MAS, Esther D Avery, Ling Zhang, Jamie Gould, Andrew Greaves, Januario E. Castro, MD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 3440.
https://doi.org/10.1182/blood.V114.22.3440.3440
Published: 2009
Journal Articles

The Relative Dependency of Chronic Lymphocytic Leukemia (CLL) Cells on Nurselike Cells for in Vitro Survival Is Associated with Overall Survival in Previously Untreated CLL Patients

Danelle James, M.D., Sonia Jain, PhD, Maryann Betty, Harrison Malone, Andrew Greaves, Laura Rassenti, PhD, Thomas J. Kipps, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 4169.
https://doi.org/10.1182/blood.V112.11.4169.4169
Published: 2008
Journal Articles

CLLU1, a Novel Molecular Marker for Minimal Residual Disease Monitoring in Chronic Lymphocytic Leukemia

Danelle James, M.D., Esther D Avery, Laura Rassenti, Ph.D., Thomas J. Kipps, M.D., Ph.D., Anne Mette Buhl, Ph.D.
Journal: Blood
Blood (2008) 112 (11): 3158.
https://doi.org/10.1182/blood.V112.11.3158.3158
Published: 2008
Journal Articles

A Phase II, Open Label Study of AT-101 in Combination with Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Evaluation of Two Dose Regimens.

Januario E. Castro, MD, Olivier J. Loria, B.S, Robier A. Aguillon, M.D, Danelle James, M.D, Cesar A. Llanos, M.D, M.Sc, Laura Rassenti, Ph.D, Brian A. Wood, B.S, Jon T. Homlund, M.D, Thomas J. Kipps, M.D, Ph.D
Journal: Blood
Blood (2007) 110 (11): 3119.
https://doi.org/10.1182/blood.V110.11.3119.3119
Published: 2007
Journal Articles

Nurselike Cells in Chronic Lymphocytic Leukemia Have Gene Expression Profiles and Functional Characteristics That Are Distinct from Those of Monocytes or Dendritic Cells.

Davorka Messmer, PhD, Tomoyuki Endo, MD, Bradley T. Messmer, PhD, Danelle James, MD, Nathan J. Zvaifler, MD, Ingo G.H. Schmidt-Wolf, MD, Kipps J. Tom, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 1183.
https://doi.org/10.1182/blood.V106.11.1183.1183
Published: 2005